我们所展示的质粒图谱主要是从文献和开放数据库中收集而来，主要是为了方便研究工作，其中一小部分质粒进行了质量控制，可供科学家使用。
所有的产品都严格仅供科学研究使用，不能应用于临床试验，包括人体摄入、注射或外用的药理学用途。
确保质粒的关键元件正确，但是我们并不能保证实验结果。页面展示的图谱序列为理论序列，可能与测序结果不一致，请自行比对后确定是否满足要求。(如果测过序，本页面一般会提供下载)
开放数据库中的大多数载体序列都没有被完全测序。如果实际序列与参考序列的相似度超过99%，则将其视为正确。
由于科学研究是在探索未知，具有很大的不确定性，在任何情况下，我们都不承担超出质粒本身的额外经济损失或责任。
This is a 3rd gen lentiviral Luciferase expression vector, CMV promoter, and Puromycin selection.
- 载体名称:
- pLenti CMV Puro LUC (w168-1)
- 载体抗性:
- Ampicillin
- 载体长度:
- 9637 bp
- 载体类型:
- Mammalian Expression, Lentiviral
- 复制子:
- ori
- 筛选标记:
- Puromycin
- 拷贝数:
- High Copy
- 启动子:
- mPGK
- 克隆方法:
- Restriction Enzyme
- 5'引物:
- CMVforw
pLenti CMV Puro LUC (w168-1) 载体图谱
质粒操作方法
1. 发货形式：质粒干粉(常温运输，存于-20度，请务必先转化提质粒后使用)
2. 收到质粒干粉后请先5000rpm离心1min，再加入20μl ddH2O溶解质粒;（质粒复测的浓度有时候与标称值差距较大，这可能是因为冻干质粒在管中的位置、复溶效率、测量偏差以及管壁的吸附导致，因此建议先转化提质粒后再使用）
3. 取1支100μl 感受态于冰上解冻10min，加入2μl质粒，再冰浴30min后，42℃热激60s，不要搅动，再冰浴2min；
4. 加入900μl无抗的LB液体培养基，180rpm震荡37℃培养45min (30℃培养1-1.5小时);
5. 6000rpm离心5min，仅留100μl上清液重悬细菌沉淀，并涂布至目标质粒抗性的LB平板上;
6. 将平板倒置37℃培养14h，如果要求是30℃则培养20h; (菌落过多则将质粒稀释后再转化；没有菌落则加入10μl质粒转化；建议不要直接转表达感受态， 要先转克隆感受态，重提质粒后再导入表达感受态);
7. 挑取单菌落至LB液体培养基中，加入对应抗生素，220rpm震荡培养14h，根据实验需要和质粒提取试剂盒说明书提取质粒。
pLenti CMV Puro LUC (w168-1) 载体序列
LOCUS V001361 9637 bp DNA circular SYN 13-MAY-2021
DEFINITION Exported.
ACCESSION V001361
VERSION V001361
KEYWORDS pLenti CMV Puro LUC (w168-1)
SOURCE synthetic DNA construct
ORGANISM synthetic DNA construct
.
REFERENCE 1 (bases 1 to 9637)
AUTHORS Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO,
Campisi J, Yaswen P, Cooper PK, Kaufman PD.
TITLE A versatile viral system for expression and depletion of proteins in
mammalian cells.
JOURNAL PLoS One. 2009 Aug 6;4(8):e6529.
PUBMED 19657394
REFERENCE 2 (bases 1 to 9637)
TITLE Direct Submission
REFERENCE 3 (bases 1 to 9637)
AUTHORS .
TITLE Direct Submission
COMMENT SGRef: number: 1; type: "Journal Article"; journalName: "PLoS One.";
date: "2009-08-6"; volume: "4(8)"; pages: "e6529"
SGRef: number: 2; type: "Journal Article"
FEATURES Location/Qualifiers
source 1..9637
/mol_type="other DNA"
/organism="synthetic DNA construct"
enhancer 1..304
/label="CMV enhancer"
/note="human cytomegalovirus immediate early enhancer"
promoter 305..508
/label="CMV promoter"
/note="human cytomegalovirus (CMV) immediate early
promoter"
primer_bind 505..529
/label="LNCX"
/note="Human CMV promoter, forward primer"
protein_bind 613..637
/label="attB1"
/note="recombination site for the Gateway(R) BP reaction"
CDS 643..2292
/label="luciferase"
/note="firefly luciferase"
protein_bind complement(2302..2326)
/label="attB2"
/note="recombination site for the Gateway(R) BP reaction"
misc_feature 2357..2945
/label="WPRE"
/note="woodchuck hepatitis virus posttranscriptional
regulatory element"
promoter 2959..3458
/label="PGK promoter"
/note="mouse phosphoglycerate kinase 1 promoter"
CDS 3479..4075
/label="PuroR"
/note="puromycin N-acetyltransferase"
LTR 4216..4449
/label="3' LTR (Delta-U3)"
/note="self-inactivating 3' long terminal repeat (LTR) from
HIV-1"
polyA_signal 4521..4655
/label="SV40 poly(A) signal"
/note="SV40 polyadenylation signal"
rep_origin 4682..4817
/label="SV40 ori"
/note="SV40 origin of replication"
promoter complement(4838..4856)
/label="T7 promoter"
/note="promoter for bacteriophage T7 RNA polymerase"
primer_bind complement(4866..4882)
/label="M13 fwd"
/note="common sequencing primer, one of multiple similar
variants"
rep_origin 5024..5479
/label="f1 ori"
/note="f1 bacteriophage origin of replication; arrow
indicates direction of (+) strand synthesis"
promoter 5505..5609
/label="AmpR promoter"
CDS 5610..6467
/label="AmpR"
/note="beta-lactamase"
rep_origin 6641..7229
/label="ori"
/note="high-copy-number ColE1/pMB1/pBR322/pUC origin of
replication"
primer_bind 7383..7400
/label="L4440"
/note="L4440 vector, forward primer"
protein_bind 7517..7538
/label="CAP binding site"
/note="CAP binding activates transcription in the presence
of cAMP."
promoter 7553..7583
/label="lac promoter"
/note="promoter for the E. coli lac operon"
protein_bind 7591..7607
/label="lac operator"
/note="The lac repressor binds to the lac operator to
inhibit transcription in E. coli. This inhibition can be
relieved by adding lactose or
isopropyl-beta-D-thiogalactopyranoside (IPTG)."
primer_bind 7615..7631
/label="M13 rev"
/note="common sequencing primer, one of multiple similar
variants"
promoter 7652..7670
/label="T3 promoter"
/note="promoter for bacteriophage T3 RNA polymerase"
promoter 7698..7924
/label="RSV promoter"
/note="Rous sarcoma virus enhancer/promoter"
LTR 7925..8105
/label="5' LTR (truncated)"
/note="truncated 5' long terminal repeat (LTR) from HIV-1"
misc_feature 8152..8277
/label="HIV-1 Psi"
/note="packaging signal of human immunodeficiency virus
type 1"
misc_feature 8770..9003
/label="RRE"
/note="The Rev response element (RRE) of HIV-1 allows for
Rev-dependent mRNA export from the nucleus to the
cytoplasm."
CDS 9188..9232
/label="gp41 peptide"
/note="antigenic peptide corresponding to amino acids 655
to 669 of the HIV envelope protein gp41 (Lutje Hulsik et
al., 2013)"
CDS 9381..9422
/note="Protein Tat from Human immunodeficiency virus type 1
group M subtype B (isolate WMJ22). Accession#: P12509"
/label="Protein Tat"
misc_feature 9499..9615
/label="cPPT/CTS"
/note="central polypurine tract and central termination
sequence of HIV-1"